NCT06302868

Brief Summary

The purpose of this study is to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (Doxy.me VR) vs. standard telemental health (TMH) to adults with intense fear of dogs, snakes, and/or spiders. The secondary purpose is to preliminarily examine the efficacy of using Doxy.me VR vs. TMH in reducing phobia severity.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 3, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 12, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 12, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2024

Completed
Last Updated

March 12, 2024

Status Verified

March 1, 2024

Enrollment Period

10 months

First QC Date

January 12, 2024

Last Update Submit

March 6, 2024

Conditions

Keywords

phobiaphobiassnakesdogsspiders

Outcome Measures

Primary Outcomes (1)

  • Phobia symptom severity

    The Severity Measure for Specific Phobia (SMSP) will be used to assess changes in phobia symptom severity at the 3 Month Follow-Up. Each item on the measure is rated on a 5-point scale (0=Never; 1=Occasionally; 2=Half of the time; 3=Most of the time, and 4=All of the time). The total score can range from 0 to 40 with higher scores indicating greater severity of specific phobia. The clinician will use an average total score, which reduces the overall score to a 5-point scale, which allows the clinician to think of the severity of the individual's specific phobia in terms of none (0), mild (1), moderate (2), severe (3), or extreme (4).

    3 Month Follow-Up

Study Arms (2)

Telemedicine-based Virtual Reality Exposure Therapy

ACTIVE COMPARATOR

This group will receive exposure therapy in a telemedicine-based Virtual Reality Clinic using virtual reality snakes, dogs, or spiders. The VR stimuli range from small to medium to large and have four activity levels: idle, calm, energetic, and aggressive.

Behavioral: Telemedicine-Based Virtual Reality Exposure Therapy

Standard Telemedicine Exposure Therapy

ACTIVE COMPARATOR

This group will receive exposure therapy via Doxy.me telemedicine platform using photos and videos of snakes, dogs, or spiders. The photo/video stimuli range from small to medium to large and have four activity levels: idle, calm, energetic, and aggressive.

Behavioral: Telemedicine Exposure Therapy Using Photos and Videos

Interventions

Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.

Standard Telemedicine Exposure Therapy

Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.

Telemedicine-based Virtual Reality Exposure Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Is an adult ≥ 18 years old
  • Has a self-reported fear of dogs, snakes, and/or spiders
  • Indicates Subthreshold or Present Specific Phobia symptoms as determined by the study therapist via administration of the Diagnostic Assessment Research Tool (DART) Specific Phobia Module
  • Has access to the internet AND a computer OR smartphone with video conferencing capabilities
  • Will reside in the state of Florida for the duration of the study

You may not qualify if:

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Is participating in ongoing mental health therapy from a non-study therapist
  • Has had changes to psychotropic medication use within six weeks preceding enrollment in the trial
  • Reports active suicidal and/or homicidal intent or plan as determined by the study therapist via administration of the Diagnostic Assessment Research Tool (DART) Risk Assessment Module
  • Reports active auditory, visual, and/or tactile hallucinations via the Diagnostic Assessment Research Tool (DART) Psychosis Module screening question
  • Reports a history of epilepsy or seizures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of South Florida

Tampa, Florida, 33613, United States

RECRUITING

Related Publications (1)

  • Schuler KR, Ong T, Welch BM, Craggs JG, Bunnell BE. Examining a Telemedicine-Based Virtual Reality Clinic in Treating Adults With Specific Phobia: Protocol for a Feasibility Randomized Controlled Efficacy Trial. JMIR Res Protoc. 2025 Apr 10;14:e65770. doi: 10.2196/65770.

MeSH Terms

Conditions

ArachnophobiaZoophobiaPhobic Disorders

Interventions

Videotape Recording

Condition Hierarchy (Ancestors)

Anxiety DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Tape RecordingAudiovisual AidsEducational TechnologyTechnologyTechnology, Industry, and AgricultureTelevision

Study Officials

  • Brian E Bunnell, PhD

    University of South Florida

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kaitlyn R Schuler, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2024

First Posted

March 12, 2024

Study Start

October 3, 2023

Primary Completion

August 1, 2024

Study Completion

August 1, 2024

Last Updated

March 12, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations